This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/domain/vavai/projekt/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/resource/domain/vavai/subjekt/
n10http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n14http://bibframe.org/vocab/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00209805%3A_____%2F13%3A%230000423%21RIV14-GA0-00209805/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00209805%3A_____%2F13%3A%230000423%21RIV14-GA0-00209805
rdf:type
skos:Concept n10:Vysledek
rdfs:seeAlso
http://link.springer.com/article/10.1007%2Fs00428-013-1459-4
dcterms:description
The TP63 gene gives rise to protein isoforms with different properties and functions due to the presence (TAp63) or absence (ΔNp63) of N-terminal p53-like transactivation domain. Immunohistochemistry for p63 has clinical value for certain tumour types, but investigations have been hampered by a lack of well characterized antibodies and the inability to discriminate between these N-terminal isoforms with opposite functional properties. We have characterized a series of monoclonal antibodies to recombinant human TAp63 and two commercial p63 monoclonals by Western blot, immunostaining and phage display epitope mapping. 28 of 29 (96.6 %) novel monoclonals that recognized all p63 isoforms showed substantial cross-reactivity with p73, as did the commercial antibody, 4A4. One novel clone, PANp63-6.1, showed slight cross-reaction with p73 by Western blotting but not immunohistochemistry and the SFI-6 monoclonal did not cross-react with p73 or p53. Phage display revealed that PANp63-6.1 epitope has one amino acid difference between p63 and p73; 4A4 epitope is identical in both, whereas SFI-6 epitope is unique to p63, accounting for these findings. We also produced and characterized TAp63-specific clone that does not recognize p53 or p73, and we prepared polyclonal sera specific for ΔNp63 isoforms. Immunohistochemistry demonstrated that TAp63 is expressed in a variety of epithelial and other cell types during development, often in a converse pattern to ΔNp63, but has a very limited expression in normal adult tissues and is independent of ΔNp63. TAp63 was expressed in 17.6 % of squamous cancers of cervix that expressed p63, unlike normal cervix where TAp63 was not expressed. TAp63 did not associate with proliferative index, but cervical carcinomas with TAp63 expression showed improved survival. These data highlight the need for rigorous antibody characterization and indicate that p63-isoform identification may improve the clinical value of p63 expression analyses. The TP63 gene gives rise to protein isoforms with different properties and functions due to the presence (TAp63) or absence (ΔNp63) of N-terminal p53-like transactivation domain. Immunohistochemistry for p63 has clinical value for certain tumour types, but investigations have been hampered by a lack of well characterized antibodies and the inability to discriminate between these N-terminal isoforms with opposite functional properties. We have characterized a series of monoclonal antibodies to recombinant human TAp63 and two commercial p63 monoclonals by Western blot, immunostaining and phage display epitope mapping. 28 of 29 (96.6 %) novel monoclonals that recognized all p63 isoforms showed substantial cross-reactivity with p73, as did the commercial antibody, 4A4. One novel clone, PANp63-6.1, showed slight cross-reaction with p73 by Western blotting but not immunohistochemistry and the SFI-6 monoclonal did not cross-react with p73 or p53. Phage display revealed that PANp63-6.1 epitope has one amino acid difference between p63 and p73; 4A4 epitope is identical in both, whereas SFI-6 epitope is unique to p63, accounting for these findings. We also produced and characterized TAp63-specific clone that does not recognize p53 or p73, and we prepared polyclonal sera specific for ΔNp63 isoforms. Immunohistochemistry demonstrated that TAp63 is expressed in a variety of epithelial and other cell types during development, often in a converse pattern to ΔNp63, but has a very limited expression in normal adult tissues and is independent of ΔNp63. TAp63 was expressed in 17.6 % of squamous cancers of cervix that expressed p63, unlike normal cervix where TAp63 was not expressed. TAp63 did not associate with proliferative index, but cervical carcinomas with TAp63 expression showed improved survival. These data highlight the need for rigorous antibody characterization and indicate that p63-isoform identification may improve the clinical value of p63 expression analyses.
dcterms:title
Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry
skos:prefLabel
Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry
skos:notation
RIV/00209805:_____/13:#0000423!RIV14-GA0-00209805
n10:predkladatel
n11:ico%3A00209805
n3:aktivita
n17:P
n3:aktivity
P(ED2.1.00/03.0101), P(GAP301/11/1678), P(NT13794)
n3:cisloPeriodika
3
n3:dodaniDat
n6:2014
n3:domaciTvurceVysledku
n8:5713021 n8:4001818 n8:9637419 n8:1267728 n8:5181682 n8:5395488 n8:3403149
n3:druhVysledku
n18:J
n3:duvernostUdaju
n7:S
n3:entitaPredkladatele
n13:predkladatel
n3:idSjednocenehoVysledku
65105
n3:idVysledku
RIV/00209805:_____/13:#0000423
n3:jazykVysledku
n20:eng
n3:klicovaSlova
p63; TAp63; development; cervical cancer
n3:klicoveSlovo
n5:p63 n5:cervical%20cancer n5:development n5:TAp63
n3:kodStatuVydavatele
DE - Spolková republika Německo
n3:kontrolniKodProRIV
[5830AE71C65C]
n3:nazevZdroje
Virchows Archiv
n3:obor
n15:EB
n3:pocetDomacichTvurcuVysledku
7
n3:pocetTvurcuVysledku
9
n3:projekt
n9:NT13794 n9:GAP301%2F11%2F1678 n9:ED2.1.00%2F03.0101
n3:rokUplatneniVysledku
n6:2013
n3:svazekPeriodika
463
n3:tvurceVysledku
Nenutil, Rudolf Müller, Petr Holčáková, Jitka Vojtěšek, Bořivoj Bouchalová, Pavla Nekulová, Miroslava Mouková, Lucie
n3:wos
000323904700007
s:issn
0945-6317
s:numberOfPages
11
n14:doi
10.1007/s00428-013-1459-4